FDA Approvals
CEL-SCI's Head and Neck Cancer Study Protocol Cleared by FDA; Seeks Commercialization Partners
Stock Titan
•
March 17, 2025
CEL-SCI's head and neck cancer registration study protocol has received FDA approval. The company is now actively seeking potential partners to help commercialize their Multikine therapy.
CEL-SCI Corporation announced that the FDA has completed its review of the company's head and neck cancer registration study protocol. This approval is a crucial step in advancing their Multikine therapy towards potential commercialization. The positive feedback from the FDA shows confidence in CEL-SCI's research and development process. The company is now actively seeking partners to collaborate on the commercialization of Multikine, highlighting the potential market impact of this treatment. A successful partnership would significantly increase the reach and accessibility of Multikine to patients needing this type of treatment.